Modality
Multispecific
MOA
FGFRi
Target
CFTR
Pathway
JAK/STAT
ET
Development Pipeline
Preclinical
~Jan 2014
→ ~Apr 2015
Phase 1
~Jul 2015
→ ~Oct 2016
Phase 2
Jan 2017
→ Jul 2026
Phase 2Current
NCT06432517
2,711 pts·ET
2024-11→2026-05·Recruiting
NCT03339713
412 pts·ET
2017-01→2026-07·Terminated
3,123 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-091mo awayPh2 Data· ET
2026-07-234mo awayPh2 Data· ET
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P2
Termina…
P2
Recruit…
Catalysts
Ph2 Data
2026-05-09 · 1mo away
ET
Ph2 Data
2026-07-23 · 4mo away
ET
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06432517 | Phase 2 | ET | Recruiting | 2711 | PANSS |
| NCT03339713 | Phase 2 | ET | Terminated | 412 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| Doxasotorasib | Samsung Biologics | Phase 2/3 | CFTR |